The company’s sodium hyaluronate pharmaceutical raw material drug workshop was put into trial operation and officially put into operation.
The company’s micro plastic injection preparation project was rated as the key project of Binzhou City 2019.
The company obtained the NSF certificate.
The company’s second phase expansion project was officially put into operation.
The company obtained a drug production license.
The company’s second-phase expansion project was rated as the key project of Binzhou City in 2016, and construction started in the second half of the year.
The company issued additional shares of 4.9 million shares and raised 27 million yuan.
The company will issue 3 million shares of the company and raise 15 million yuan.
The company officially listed three boards.
The company underwent joint-stock reform, formally renamed Shandong AWA Biopharm Co., Ltd.
The company officially put into production.
The company was formally established, and Binzhou Anhua Bioengineering Co., Ltd. was registered in Binzhou.